| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 22.396 | 23.346 | 59.825 | 0 | 0 | 0 | 0 | 0 | 0 | 19.422 |
| Total Income - EUR | 22.396 | 23.346 | 59.825 | 0 | 0 | 0 | 0 | 0 | 0 | 19.422 |
| Total Expenses - EUR | 2.841 | 1.850 | 6.046 | 748 | 219 | 149 | 81 | 81 | 962 | 17.592 |
| Gross Profit/Loss - EUR | 19.555 | 21.496 | 53.778 | -748 | -219 | -149 | -81 | -81 | -962 | 1.829 |
| Net Profit/Loss - EUR | 18.883 | 20.795 | 53.180 | -748 | -219 | -149 | -81 | -81 | -962 | 1.543 |
| Employees | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Check the financial reports for the company - Oftaclinic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 21.804 | 29.779 | 62.067 | 7.149 | 6.792 | 6.514 | 6.288 | 6.227 | 5.968 | 5.772 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 24.495 | 50.349 | 0 | 0 | 0 | 0 | 0 | 0 | 153 |
| Cash | 21.804 | 5.284 | 11.718 | 7.149 | 6.792 | 6.514 | 6.288 | 6.227 | 5.968 | 5.619 |
| Shareholders Funds | 20.232 | 28.978 | 61.225 | 7.149 | 6.792 | 6.514 | 6.288 | 6.227 | 5.245 | 6.759 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.572 | 801 | 843 | 0 | 0 | 0 | 0 | 0 | 723 | 676 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oftaclinic Srl